SCHEMBL25904154

SCHEMBL25904154

CC(C)(C)CCOC1CCN(C(=O)C(C)(C)C)CC1

nearest known ligand 0.35

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
NAMPT P43490 2/20 0.34
DRD2 P14416 1/20 0.33
DRD4 P21917 1/20 0.33
DRD3 P35462 1/20 0.33
LSS P48449 1/20 0.32
MEN1 O00255 1/20 0.32
KMT2A Q03164 1/20 0.32
IDO1 P14902 1/20 0.32
AOC2 O75106 1/20 0.32
HCRTR2 O43614 1/20 0.32
DPP4 P27487 1/20 0.32
KDM4E B2RXH2 1/20 0.32
ALDH1A1 P00352 1/20 0.32
LMNA P02545 1/20 0.32
MAPT P10636 1/20 0.32
CASP3 P42574 1/20 0.31
LIPG Q9Y5X9 2/20 0.31
LIPC P11150 1/20 0.31
CXCR3 P49682 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL13677293 0.85 TAAR1 (0.37) NAMPTDRD2DRD4DRD3LSS
SCHEMBL13223559 0.81 GAA (0.38) NAMPTDRD2DRD4DRD3MEN1
SCHEMBL13676891 0.81 HCRTR2 (0.40) NAMPTDRD2DRD4DRD3LSS
SCHEMBL23328751 0.81 TEAD1 (0.45) LSSLMNA
SCHEMBL23364561 0.79 LIPG (0.37) KDM4EALDH1A1LMNAMAPTLIPG
SCHEMBL23364562 0.79 LIPG (0.37) KDM4EALDH1A1LMNAMAPTLIPG
SCHEMBL26750043 0.79 NAMPT (0.37) NAMPTDRD2DRD4DRD3MEN1
SCHEMBL26751017 0.79 ITGB3 (0.43) NAMPTMEN1KMT2AAOC2CASP3
SCHEMBL18701885 0.77 CYP3A4 (0.38) NAMPTDRD2DRD4DRD3AOC2
SCHEMBL25904071 0.76 CXCR3 (0.38) DRD2DRD4DRD3MEN1KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230234936-A1 COMPOUND FOR TARGETING AND DEGRADING PROTEIN, AND PREPARATION METHOD THEREFOR AND USE THEREOF LEADINGTAC PHARMACEUTICAL (SHAOXING) CO., LTD. (CN) 2023-07-27 US disclosed
US-20230234936-A1 COMPOUND FOR TARGETING AND DEGRADING PROTEIN, AND PREPARATION METHOD THEREFOR AND USE THEREOF LEADINGTAC PHARMACEUTICAL (SHAOXING) CO., LTD. (CN) 2023-07-27 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230234936-A1 COMPOUND FOR TARGETING AND DEGRADING PROTEIN, AND PREPARATION METHOD THEREFOR AND USE THEREOF IRAK4, IRAK2, IRAK1 NAMPT 2021/4885DRD2 4831/4885DRD4 4747/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.